Forte Biosciences (FBRX) Corporate presentation summary

Mission, vision, and strategy

• Aims to advance precision immunotherapies targeting autoimmune disease drivers for transformative patient outcomes and shareholder value.

• Strategy leverages robust preclinical and proprietary clinical data to develop disease-modifying therapies for IL-2/IL-15 axis-dependent immune pathways.

• Vision is to lead in developing next-generation biologics inhibiting CD122, addressing unmet needs in autoimmune and inflammatory diseases.

Scientific rationale and mechanism of action

• CD122 is a key subunit of IL-2/IL-15 receptors on NK and T cells, and part of the high-affinity IL-2 receptor on Tregs.

• FB102, an anti-CD122 antibody, blocks IL-2/IL-15-driven proliferation of pathogenic T and NK cells while sparing Tregs, maintaining immune regulation.

• In vitro data show FB102 inhibits T and NK cell proliferation and inflammatory cytokine production, but does not inhibit Treg proliferation.

Clinical and preclinical development

• FB102 demonstrated positive Phase 1b data in celiac disease, with statistically significant improvements in histology, inflammation, and symptoms versus placebo.

• Preclinical models show efficacy in celiac disease, vitiligo, alopecia areata, and type 1 diabetes, supporting a pipeline-in-a-product approach.

• Phase 2 celiac disease trial to start 2H25, topline data expected 2026; Phase 1b trials in vitiligo and alopecia areata enrolling, topline data expected 2026.